Last Updated: June 9, 2026

Dial Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for DIAL

DIAL has two approved drugs.



Summary for Dial
US Patents:0
Tradenames:3
Ingredients:2
NDAs:2

Drugs and US Patents for Dial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dialysis Sups NORMOCARB HF 25 magnesium chloride; sodium bicarbonate; sodium chloride SOLUTION;INJECTION 021910-001 Jul 26, 2006 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Dialysis Sups NORMOCARB HF 35 magnesium chloride; sodium bicarbonate; sodium chloride SOLUTION;INJECTION 021910-002 Jul 26, 2006 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Dial DIAL hexachlorophene SOLUTION;TOPICAL 017421-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Dial

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Dialysis Sups NORMOCARB HF 25 magnesium chloride; sodium bicarbonate; sodium chloride SOLUTION;INJECTION 021910-001 Jul 26, 2006 5,945,449 ⤷  Start Trial
Dialysis Sups NORMOCARB HF 35 magnesium chloride; sodium bicarbonate; sodium chloride SOLUTION;INJECTION 021910-002 Jul 26, 2006 5,945,449 ⤷  Start Trial
Dialysis Sups NORMOCARB HF 25 magnesium chloride; sodium bicarbonate; sodium chloride SOLUTION;INJECTION 021910-001 Jul 26, 2006 7,300,674 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Dial Competitive Landscape Analysis: Market Position, Strengths, and Strategic Insights

Last updated: April 25, 2026

Where does Dial sit in the market?

Dial’s branded position is strongest in categories where it has established consumer familiarity, distribution breadth, and pricing leverage. Competitive pressure concentrates in mass-market personal care and adjacent household hygiene, where private label and large incumbents compete on promotional intensity, shelf placement, and reformulation cycles.

Dial’s competitive field typically splits into four groups:

  1. Large branded incumbents (global and national leaders with scale manufacturing and marketing budgets)
  2. Specialty and premium hygiene brands (skin-care and dermatologist-led positioning)
  3. Private label / retailer brands (cost-first propositions, fast copy cycles)
  4. New entrants and subscription DTC players (limited scale, but momentum via claims and channels)

Dial’s practical market position in these environments comes from:

  • Retail reach: wide channel presence across grocery, drug, and mass formats.
  • Brand recall: consumer recognition that supports faster trial-to-repeat.
  • Manufacturing and supply: the ability to cover high-turn volumes during promotional windows.
  • Category adaptability: reformulation and variant rollout that maintains shelf relevance.

What are Dial’s core strengths in competitive terms?

Dial’s defensibility is not tied to a single product feature. It is tied to execution across brand, supply, and category management.

Brand and demand

  • High consumer recognition in mainstream hygiene use cases.
  • Clear functional intent (cleaning, protection, skin comfort positioning), which reduces the friction of switching in mass formats.
  • Variant portfolio management that supports assortment rotation with seasonal demand.

Distribution and trade economics

  • Slotting and promotional capability to retain shelf space when promotions intensify.
  • Forward replenishment discipline that reduces out-of-stocks during peak periods and promotions.
  • Retailer-friendly packaging and SKU cadence that sustains presence across multiple store formats.

Manufacturing and cost control

  • Scale procurement and capacity utilization that help absorb commodity and freight variability.
  • Operational consistency that reduces batch variability risk in routine hygiene formats.

Product development agility

  • Incremental reformulations and variants that keep the brand competitive without resetting the entire platform.
  • Claims and sensory adjustments aligned to consumer preferences and retailer performance metrics.

Who are Dial’s main competitive threats?

Threat intensity rises where competitors can undercut pricing, capture endcaps, or shift consumer preference through differentiated claims.

Threat profile

Competitor archetype Main attack vector Typical impact on Dial
Large branded incumbents Trade spend + broad assortment Share pressure during event promotions
Premium/specialty hygiene Claim-driven differentiation (skin sensitivity, efficacy) Displacement in higher AUR segments
Private label Price compression + rapid copy Margin erosion in commodity segments
DTC/new entrants Targeted messaging + social proof Limited near-term share, but claim pressure risk

How does Dial’s competitive strategy tend to work?

Dial’s strategic playbook in hygiene categories usually maps to four recurring actions:

  1. Defend household penetration
    Keep baseline products permanently available and paired with seasonal or benefit variants.

  2. Win promotional windows without margin collapse
    Use trade strategy that balances volume uplift with controlled discount depth, protecting gross margin.

  3. Maintain assortment relevance
    Prioritize SKUs that deliver store-level velocity. Reduce or rotate slower movers during reset cycles.

  4. Use formulation and claims to justify pay-up
    Focus claims that retailers can support in planograms (skin feel, irritation reduction, scent preferences, and protection framing).

What is the R&D and IP relevance in this landscape?

For mass-market hygiene and related personal care, patent defensibility often matters less than formulation know-how, process control, branding, and retail execution. Where patents matter, they typically cluster around:

  • Formulation inventions (combinations, surfactant systems, antimicrobial actives, skin-conditioning agents)
  • Use claims tied to specific performance parameters
  • Manufacturing processes (stability, emulsification, shelf-life extension)
  • Packaging and dosing systems (less common, but can be meaningful in some product lines)

In this competitive landscape, the most actionable implication for Dial-type players is that IP strategy must support commercial speed: faster variant launches and incremental reformulation that retains regulatory comfort and quality consistency.

How should Dial position against private label?

Private label is a structural threat in commodity hygiene categories. Dial’s counter is to compete where “value” is not purely price.

Practical positioning levers:

  • Skin feel and irritation comfort claims that are harder for private label to replicate credibly without consumer testing.
  • Brand-led trust: differentiate on consistent performance and familiarity.
  • Performance-to-price framing during promotions, not just headline discounting.

Execution implications:

  • Optimize SKU mix so value-movers do not cannibalize flagship margin.
  • Use size and format strategy (where retailer economics allow) to reduce private label shelf advantage.

Where do scale players pressure Dial most?

Large branded incumbents use three high-frequency tactics:

  • Sustained promotional intensity that compresses category price floors
  • Assortment breadth that forces retailers to trade space at a high opportunity cost
  • Technology transfer and rapid reformulation that shifts consumers toward “better” mainstream options

Dial’s counter is to maintain strong in-store availability and to ensure that promotional products map to consumer demand rather than just trading pressure.

Strategic insights: what Dial should do next

Dial’s highest-return strategies in a competitive hygiene market typically concentrate on measurable commercial outcomes: velocity, shelf share, margin protection, and claim credibility.

1) Tighten assortment discipline around store-level ROI

  • Cut SKUs that do not justify shelf space.
  • Expand only those variants that can be supported by sustained retail marketing or repeat purchase data.

2) Protect margin during promotional peaks

  • Structure promotions with clear guardrails on discount depth and SKU mix.
  • Align promotional mechanics to margin-safe bundles and formats.

3) Build defensible differentiation through claims that retail can validate

  • Claims must map to consumer perception and retailer performance data.
  • Prioritize reformulation and sensory improvements that reduce switching.

4) Convert brand recognition into higher AUR

  • Drive “upgrade” paths: baseline users should have a reason to trade into higher-priced variants (skin comfort, protection framing, scent preferences).

What does this mean for investors or R&D planning?

Dial’s competitive advantage is likely to be realized through commercial execution rather than one-off breakthroughs. The market rewards:

  • Trade execution quality (shelf retention, promotion ROI)
  • Manufacturing reliability (no stockouts, consistent quality)
  • Product cadence aligned with consumer search and retailer planograms

For R&D planning, the implication is to prioritize programs that reduce time-to-variant while maintaining formulation safety, stability, and consistent sensory outcomes.


Key Takeaways

  • Dial competes most directly in mainstream hygiene where shelf presence, promotional economics, and brand recall decide share.
  • The main threats are large branded incumbents (trade spend and breadth) and private label (price compression).
  • Dial’s strengths are practical: distribution breadth, brand familiarity, manufacturing consistency, and incremental variant execution.
  • The highest-return strategy is to tighten assortment ROI, protect margin during promotions, and focus claims that translate into repeat purchase and retailer support.

FAQs

1) What competitors most affect Dial’s mainstream category share?
Large branded incumbents and private label typically drive the strongest competitive pressure through promotions and pricing.

2) Does Dial’s advantage come from patents?
In mass-market hygiene, commercial execution and formulation know-how usually matter more than single patents; where IP exists, it supports incremental differentiation and process reliability.

3) How can Dial defend against private label without racing to the lowest price?
Dial can compete on credible skin-comfort and performance claims, maintain trust advantages, and manage promotions with guardrails on discount depth.

4) What should Dial prioritize in product development?
Variants that improve consumer-perceived performance (skin feel, comfort, protection framing) while preserving stability and consistent sensory outcomes.

5) What metrics best track Dial’s competitiveness?
Store-level velocity, share of shelf, promotional ROI, gross margin by SKU, and repeat purchase rates on upgraded variants.


References

[1] Bloomberg Industry Data (accessed via internal editorial system).
[2] Procter & Gamble: Annual Reports and product portfolio disclosures (company filings).
[3] Unilever: Annual Reports and product segment disclosures (company filings).
[4] FDA: Guidance on OTC drug claims and labeling principles (relevant for claim substantiation frameworks).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.